What 'melanosis coli' means on your colonoscopy report

Start with the name, because the name is the first thing that frightens people and it is a documented mistake. Cruveilhier described the dark colon in 1829, and Virchow gave it the name melanosis coli in 1857. The pigment stained positive with a dye called Masson-Fontana, which is a melanin stain, so melanin is what everyone assumed it was. That turned out to be a cross-reaction. The pigment is lipofuscin, a waste product of cell breakdown, which is why the alternative term pseudomelanosis coli is also used, and why you may see that word on your report (Liu and colleagues, PLoS One, 2017; StatPearls, 2025).

So the plain-English version. Anthraquinone laxatives, the senna family, pass through the stomach and small intestine inactive and only switch on when bacteria in the colon act on them. That is why this is a colon finding and never a stomach one. In the colon they speed up the natural turnover of the surface cells, and those cells die off in an orderly way that biologists call apoptosis. Scavenger cells called macrophages, sitting in the layer just under the surface, clean up the debris. What they cannot fully break down stays behind as lipofuscin. Load enough of those cells with enough pigment and the lining looks brown or black through the scope (Walker and colleagues, American Journal of Pathology, 1988; StatPearls).

Three things follow from that, and they are worth holding on to. The pigment sits inside cells in the wall, so it is not a stain on the surface that anyone could wipe off, and it is not a hole or a scar. The lining underneath is structurally intact, which is exactly why a pathologist can look at the same slide and write that there is no colitis and no dysplasia. And because the pigment is being carried by cells that turn over, it clears when the cause stops. This is a finding that undoes itself.

The direct answer first, because you should not have to read three paragraphs to get it. Melanosis coli is not cancer, is not precancerous, and is not associated with an increased risk of colon cancer (StatPearls, 2025). The reference text puts it as plainly as a reference text ever does: it is not precancerous or fatal, and it can improve with cessation.

The most useful fact behind that answer is a visual one. Polyps do not take up the pigment. Adenomas and even carcinomas stay their own pale color while the lining around them darkens, so a small polyp that would have blended into a pink wall now sits against a brown one and separates cleanly (StatPearls; Freeman, 2008). Gastroenterologists have a phrase for it. One team described melanosis coli as producing a "chromo-endoscopy-like effect," borrowing the name of a technique where dye is deliberately sprayed on the lining to make lesions pop (Abu Baker and colleagues, 2018).

That explains the numbers that look alarming at first glance. A matched case-control study at a US academic center found adenomas in 34.7 percent of people with melanosis coli versus 26.5 percent without, an odds ratio of 1.52 (95 percent confidence interval 1.04 to 2.24). Here is the detail that decides how to read it: the effect was confined to adenomas 5 millimeters and smaller, and the authors attributed it to exactly the contrast effect above (Blackett and colleagues, Journal of Clinical Gastroenterology, 2018). A cause that made polyps grow would not politely stop at 5 millimeters. Better eyesight for small things would.

The rest of the literature reads the same way. An Israeli series found polyps in 33.4 percent versus 21.8 percent (Abu Baker and colleagues, 2018). A 2017 series found more low-grade adenomas but no difference in high-grade dysplasia or adenocarcinoma, though the authors noted there were too few of those lesions to draw a firm conclusion, and it found no relationship between how dark the pigment was and how many polyps turned up (Liu and colleagues, 2017).

The larger pooled looks agree. A 2022 study found a higher polyp detection rate alongside fewer polyps 10 millimeters and larger and lower detection of advanced adenomas and adenocarcinoma, and concluded that melanosis coli is not associated with histological progression of polyps (Zhang and colleagues, Journal of Digestive Diseases, 2022). A 2021 meta-analysis pooling five studies found more polyps and adenomas in people with melanosis coli, and no difference in adenocarcinoma (Katsumata and colleagues, International Journal of Colorectal Disease, 2021). And a 1993 cohort of 2,277 patients found no increase in colorectal cancer in laxative users or in people with melanosis coli, and named the detection problem at the time (Nusko and colleagues, 1993).

The honest version, then, is this. More small adenomas get found in a pigmented colon, and a handful of papers do argue that something biological might be going on rather than something optical, including the 2017 series itself, whose authors titled their paper with a question: "Harmless pigmentation?" But every analysis that has sorted the finding by size or by grade points the same way: the small ones go up, the dangerous ones do not, and the darkness of the pigment predicts nothing. Finding more small polyps is what a colonoscopy is for, and each one found is one removed.

The best modern number comes from a study of 342,922 colonoscopies, which found melanosis coli in 1.78 percent of them (95 percent confidence interval 1.73 to 1.82). It rises steeply with age: 0.58 percent in people 25 and under, 1.22 percent between 25 and 59, and 3.19 percent at 60 and over (Wang and colleagues, PeerJ, 2018). The Israeli series above, covering roughly 51,000 colonoscopies over 15 years, found it in 1.4 percent (Abu Baker and colleagues, 2018), and the classic American series from 1958 sits in the same neighborhood at 0.8 to 1.1 percent (Wittoesch, cited in StatPearls).

Those are all colonoscopy numbers, which is deliberate. You will find much larger percentages quoted online that come from autopsy studies of a very different population, and mixing the two produces a number that describes nobody. If you want to know how often a gastroenterologist sees this in a day of scopes, the colonoscopy figures are the honest ones.

Where it sits varies. It tends to be most obvious in the proximal colon (the right side) and the cecum, and it can involve any segment or the whole thing (StatPearls; Freeman, World Journal of Gastroenterology, 2008). One large series found left-sided pigment just as often (Liu and colleagues, 2017). And in almost every case it causes no symptoms at all. It is found because someone was looking at the colon for another reason.

Two of the pages that rank for this word carry the same sentence: 11.9 percent of colon cancer patients had melanosis coli. It is presented with no context, and in that form it sounds like a risk. That figure has a source, and the source says something different. A 2017 study looked at 436 people who had colon cancer and found that 52 of them, or 11.9 percent, also had melanosis coli (Biernacka-Wawrzonek and colleagues, 2017). Read the direction of that fraction carefully: it is the share of cancer patients who had the pigment, which is a completely different question from the share of people with pigment who get cancer. The authors were explicit in their own paper that they were not able to establish a relationship between the two. The figure travels the internet without that sentence attached.

A second scare comes from a major health site that pairs melanosis coli with a large cancer-risk multiple. That number belongs to Peutz-Jeghers syndrome, an inherited condition that causes its own pigmented spots and its own type of polyp, and that carries real, well-documented risk. It is a separate diagnosis with a separate cause. Sharing a paragraph on a web page is the only thing it shares with laxative pigment.

The third source of confusion is the word itself. Melano- reads as melanoma to almost everyone who is not a pathologist, and that is a naming accident from 1857 that no one has been able to undo. The pigment is lipofuscin, not melanin, and there are no pigment cells of the kind melanoma comes from, and the two conditions are unrelated in origin, behavior, and meaning.

The class that causes melanosis coli is the anthraquinones, sometimes written anthranoids. In practice that means four things. Senna and sennosides, by far the most common, sold as Senokot, Ex-Lax, senna tea, and as the senna in many combination products. Cascara sagrada. Aloe, specifically the bitter yellow latex just under the leaf skin, not the clear gel people put on sunburn. And rhubarb root, which caused biopsy-proven melanosis coli in one documented case as the only product involved (StatPearls; Freeman, 2008; Klair and colleagues, ACG Case Reports Journal, 2019).

The hidden sources are the ones that catch people out, and they are the reason so many readers arrive at this page certain they never took a laxative. Herbal teas sold for dieting, slimming, detoxing, or a nightly tea that reliably works by morning, frequently contain senna. A state laboratory analysis published in 1998 found sennosides in dieter's teas on the market (Liao, 1998), and a 2024 case report describes biopsy-proven melanosis coli in someone drinking a herbal tea (Bizuneh and colleagues, 2024). Herbal weight-loss supplements are the other common carrier, so it is worth reading the ingredient list of anything you take at night for senna, cascara, or aloe.

The products not known to cause mucosal pigmentation start with the ones StatPearls names as the alternatives, and the phrasing there is deliberate: polyethylene glycol, sold as MiraLAX and used in colonoscopy prep; bisacodyl, sold as Dulcolax; fiber supplements such as psyllium (Metamucil), methylcellulose (Citrucel), and wheat dextrin (Benefiber); and the prescription secretagogues, the class that includes linaclotide (Linzess), lubiprostone (Amitiza), and plecanatide (Trulance). Osmotic laxatives such as magnesium and lactulose, and stool softeners such as docusate, are also outside the anthraquinone class, and we found no reports linking them to the pigment.

On timing: the pigment can appear within only a few months of regular anthraquinone use (StatPearls), and one series documented two cases where it developed in under six months (Liu and colleagues, 2017). It does not necessarily take years, which is another reason people are surprised to see it on a report.

This deserves its own section, because it is a real and common situation, and because the way this finding gets written about online can make someone feel accused of something.

The evidence is clear that anthraquinones are not the only route. In a series of patients who had both melanosis coli and inflammatory bowel disease, only 5 of 25, that is 20 percent, had any documented laxative use (Pardi and colleagues, 1998). A 1997 study concluded that the majority of cases in its series were not laxative-associated, and described melanosis coli instead as a non-specific marker of increased cell turnover with many possible causes (Byers and colleagues, 1997). And a 2021 Japanese study of 690 patients, published alongside a meta-analysis, found that only 50.9 percent of people with melanosis coli were regular anthranoid users, against 6.5 percent of the comparison group (Katsumata and colleagues, 2021). That last pair of numbers says both things at once: the association with senna is real and strong, and about half the people who have this were not regular users of it.

So there are three good answers when the finding does not match your memory. You may have taken an anthraquinone without filing it as a laxative, most often as a tea or a supplement. Anything that speeds up the turnover of colon surface cells can in principle produce the same pigment, which is what the 1997 study meant. Or it may simply be one of the cases medicine cannot currently trace to a cause.

What is worth doing is not defending yourself. It is bringing the actual list to your doctor: every prescription, every over-the-counter product, every supplement, and every tea. That list is more useful than any explanation, and it is the kind of thing worth keeping written down in one place rather than reconstructed from memory in an exam room.

You may be holding one document or two. The colonoscopy report is written by the doctor who did the procedure and describes what the colon looked like. The pathology report is written by a pathologist who looked at the biopsy under a microscope. Melanosis coli can appear on either, and they use different vocabulary.

A pathology sign-out for this typically looks something like: "COLON, RANDOM BIOPSIES: PSEUDOMELANOSIS COLI. NEGATIVE FOR ACTIVE COLITIS. NEGATIVE FOR DYSPLASIA." Read those three lines as a set. The first names what was found. The second and third are the answers to the questions that actually mattered, and both came back the way you want them. Negative for dysplasia means no precancerous change was seen. Negative for colitis means no inflammation. The frightening-sounding line is the only positive one, and it is the benign one.

Some specific phrases, translated. "Pigment-laden macrophages in the lamina propria" is the diagnosis written literally: scavenger cells holding pigment, sitting in the thin layer of tissue just beneath the surface lining. That is the microscope description of exactly what section one described. "Consistent with melanosis coli" or "suggestive of melanosis coli" is pathologist confidence language, and it is about how firmly the appearance matches a known pattern, not about whether something dangerous might be hiding. "Diffuse" means widespread through the segment sampled, not severe. "Mild" refers to how much pigment there is. And if the report mentions a PAS stain, that is a dye used to confirm that the pigment is lipofuscin (StatPearls).

One practical note on codes, since the billing paperwork often arrives before the explanation does. There is no ICD-10 code specific to melanosis coli. It is coded as K63.89, "Other specified diseases of intestine," a billable code that lists melanosis coli among its approximate synonyms (verified at icd10data.com, 2026 edition). A generic-looking code on a bill is not a sign that anyone was vague about the diagnosis. It is a sign that the code set has no dedicated slot for a finding this benign.

If your colonoscopy report assigns a grade, it is almost certainly using the endoscopic scale from a 2017 study, and the definitions are worth quoting because no consumer page carries them. Grade I is "light brown colonic mucosa with no apparent boundary with normal mucosa." Grade II is "brown colonic mucosa, with clear linear or non-continuous boundary with normal mucosa." Grade III is "dark black colonic mucosa with linear or spotted boundary with normal mucosa" (Liu and colleagues, 2017).

In that study of 219 cases, Grade I accounted for 62.6 percent, Grade II for 25.1 percent, and Grade III for 12.3 percent. So most people who get graded land at Grade I.

The grade matters less than the number suggests. The grade measures how dark the pigment is and how sharply it borders normal-looking lining. It does not measure how much damage there is, how long you have this, or how worried anyone should be. The same study found no relationship between grade and polyp findings, and a 2022 study found that melanosis coli is not associated with histological progression of polyps at all (Liu and colleagues, 2017; Zhang and colleagues, 2022). Grade III is darker than Grade I. It is not worse than Grade I in any sense that changes what happens next.

People often read the biopsy as the alarming part, on the reasoning that nobody biopsies something harmless. The reasoning is backwards here. A gastroenterologist who sees dark lining takes a sample precisely so that the benign explanation can be confirmed rather than assumed, and the sample is what allows the pathologist to write "negative for dysplasia" in your chart instead of leaving the question open.

Dark bowel has look-alikes worth ruling out. A published case describes a surgical team encountering darkly pigmented bowel and reading it as dead, ischemic tissue, with the melanosis coli diagnosis coming afterwards (Permanente Journal, 2019). Melanoma involving the gastrointestinal tract is rare but real, and the biopsy is what settles the question. Inflammation and dysplasia are the routine questions any colon biopsy answers. Your report answering all of them at once is the whole value of having taken the sample.

So when the pathology comes back naming melanosis coli and negating everything else, someone has already done the checking on your behalf. That is a closed question, not an open one.

There is no treatment for the pigment, because there is nothing in it to treat. No medication clears it faster, no procedure removes it, and no diet does anything to it. The only intervention that exists is upstream: if an anthraquinone is behind it, stopping the anthraquinone lets the pigment clear on its own (StatPearls).

On timing, the sourced range is months to about a year. StatPearls puts resolution at several months to a year; a case report describes it as usually within a year after stopping (Klair and colleagues, 2019). The most concrete documented example is a patient who switched from senna to polyethylene glycol and had a clean-looking colonoscopy 7 months later (Chiba and colleagues, 2024). You will see a confident "6 to 12 months" quoted in a lot of places. We could not trace the 6 to a primary source, so we are not going to print it as one.

Do not simply stop a laxative you depend on without a plan. Rebound constipation after stopping is a recognized thing (StatPearls), and it is easy to read as proof that the colon is broken when it is really the predictable gap while normal habits reassert themselves. The usual sequence a clinician will walk you through is fluid, fiber, and movement first, then a non-anthraquinone product if one is needed. Stimulant laxatives of this family are designed for short-term use rather than nightly use, which is the actual point behind the whole finding.

The "lazy bowel" fear deserves an honest answer rather than a comfortable one. The idea that long-term stimulant laxative use permanently damages the nerves of the colon, sometimes called "cathartic colon" or "lazy bowel," is contested, and it is not settled either way. What we can say precisely: the pigment itself is not evidence of a damaged colon, since it sits in scavenger cells and clears. And the 2023 joint AGA and ACG guideline on chronic constipation does not mention melanosis coli anywhere in its text, while noting that there are no long-term human safety studies of senna (Chang and colleagues, 2023). That is a real gap in the evidence, and it is different from a demonstrated harm.

As for follow-up: we found no United States guideline recommending a repeat colonoscopy for melanosis coli itself. Your next colonoscopy date is set by what was found, meaning any polyps and what type they were, and by your own risk factors. If a tubular adenoma or a sessile serrated lesion is also on the report, that line sets the interval. The pigment does not.

This is the part KeptWell was built for. Upload the colonoscopy report and the pathology report and they are read, dated, and explained: the pigment line in plain English, the source shown, never a diagnosis. Both documents live in one organized place next to the ones from last time, so the question that settles this finding, whether the pigment is fading, has an answer you can actually check. Because these are medical records, they stay private to your circle: we will not sell them, show ads against them, or hand them to insurers, ever.